Like CenterWatch, Inc.

closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/11/2019 via PR Newswire

Corrona, Inc., acquired HealthiVibe LLC

synopsis: Corrona, LLC, a leading provider of real-world observational and syndicated registry data, announced that it has acquired HealthiVibe, LLC, a leading patient experience company. HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives of the product lifecycle.
buyer parent: Great Point Partners
buyer: Corrona, Inc.
Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. "
target: HealthiVibe LLC
HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives of the product lifecycle. They leverage models and online analytic platforms to provide tools to optimize clinical trials and enhance product commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/15/2016 via PR Newswire

The WIRB-Copernicus Group, will purchase Clinical Trial Applications from karmadata

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality of clinical research, will acquire from karmadata a suite of proprietary applications designed to facilitate the management of clinical trial data. karmadata is the market leader in clinical trial database and decision support applications.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
seller: karmadata
Karmadata is able to standardize and link the world's healthcare data ranging from leading open data sources to priva pharmacy and medical claims. Its propriety applications are designed to facilitate the management of clinical trial data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2006 via BNC Analysis

Informa plc, acquired Citeline

synopsis: Informa plc, the leading provider of business intelligence and strategic services to the global telecoms and media markets has acquired Citeline, Inc., the leading provider of global clinical trials intelligence to the pharmaceutical industry.
buyer: Informa plc (LSE:INF:$3,663.05)
Informa plc is the leading international provider of specialist information and services for the academic and scientific, professional and commercial business communities. "
target: Citeline
Citeline developes innovative intelligence solutions for pharmaceutical and biotechnology companies. Citeline enhances the competitive position of its clients by providing actionable information about competitors' worldwide clinical development activities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2019 via BNC Analysis

Genstar Capital LLC, acquired Advarra

synopsis: Genstar Capital, a private equity firm focused on investments in financial services, healthcare, industrial technology, and software industries, has acquired Advarra, a leading provider of institutional review board, institutional biosafety committee, and research quality and compliance solutions that are critical to the drug development process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that actively invests in high quality companies. Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. "
target parent: Linden Capital Partners
target: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/26/2020 via PR Newswire

Arsenal Capital Partners, acquired BresMed Health Solutions Ltd

synopsis: Arsenal Capital Partners, a leading private equity firm investing in healthcare and specialty industrials companies, announced the acquisition of BresMed Health Solutions, a pioneer in providing health economic research, communications, and consulting services to the global pharmaceutical industry.
buyer: Arsenal Capital Partners
Arsenal is a leading private equity firm that specializes in investments in middle‐market specialty industrials and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, and completed more than 45 platform investments. "
target: BresMed Health Solutions Ltd
BresMed is a health economic and outcomes research consultancy that provides health economic solutions to the global pharmaceutical industry. Established in 2006, BresMed has more than 150 staff across offices in the U.K., Ireland, the Netherlands, the U.S., and India.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2013 via Yahoo, Inc.

Elsevier B.V., acquired Aureus Sciences

synopsis: Elsevier announced the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies. Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles. "
target: Aureus Sciences
Aureus Sciences provides scientific databases and software applications for researchers involved in the drug discovery and development process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/29/2010 via PR Newswire

Thomson Scientific & Healthcare, acquired GeneGo Inc.

synopsis: Thomson Reuters announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development. Effective immediately, GeneGo will become part of the Healthcare & Science business of Thomson Reuters.
buyer parent: Thomson Reuters
buyer: Thomson Scientific & Healthcare (:$964.58)
Thomson Scientific & Healthcare provides integrated information solutions to researchers and librarians, physicians and pharmacists, and other professionals worldwide. "
target: GeneGo Inc.
GeneGo is a leading provider of data mining & analysis solutions in systems biology. GeneGo's data mining tools and databases help to capture and define the underlying biology behind different types of high-throughput experimental data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/22/2020 via PR Newswire

Clarivate Analytics, will acquire Decision Resources Group

synopsis: Clarivate Analytics plc, a global leader in providing trusted insights and analytics, will acquire Decision Resources Group ("DRG"), a premier provider of high-value data, analytics and insights products and services to the healthcare industry, from Piramal Enterprises Limited, part of global business conglomerate Piramal Group.
buyer: Clarivate Analytics (:$964.58)
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management. "
target parent: Piramal Group
target: Decision Resources Group
Decision Resources Group (DRG) is uniquely positioned to help healthcare businesses improve the lives of patients around the world by creating patient-centric commercial strategies that drive better outcomes and better access.
price ($mm)
$950
rev ($mm)
$207
EBITDA ($mm)
$48
EV / rev
4.6x
EV / EBITDA
20.0x
closed 5/21/2019 via BusinessWire

Xcenda, acquired Dymaxium, Inc.

synopsis: Xcenda, a part of AmerisourceBergen, announced the acquisition of Dymaxium, a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
buyer parent: AmerisourceBergen Corporation
buyer: Xcenda
Xcenda, part of AmerisourceBergen, is a strategic consultancy with 20+ years of experience applying real-world expertise in health economics and outcomes research, reimbursement, stakeholder insights, and market access consulting and communications. "
target: Dymaxium, Inc.
Dymaxium is a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via PR Newswire

Decision Resources Group, acquired Context Matters

synopsis: Decision Resources Group announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Context Matters
Context Matters is led by a team with extensive experience in the pharma & biotech and financial & information sectors with deep operational familiarity of the issues facing the pharmaceutical industry and those following the industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2016 via BNC Analysis

M3, Inc., will acquire Vidal Group

synopsis: Electra Partners’ portfolio company AXIO Group has received a binding offer from M3 Inc. to purchase Vidal Group, a European provider of reference drug information. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients with on-line access to up-to-date drug databases and related treatment-based information.
buyer: M3, Inc. (TSE:2413:$1,127.03)
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet. "
target parent: Electra Partners LLP
target: Vidal Group
Vidal Group is a leading European healthcare informatics and information systems company. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients across Europe with on-line access to up-to-date drug databases and related treatment-based information.
price ($mm)
$133
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/30/2016 via BNC Analysis

Affinity Equity Partners, will acquire MedicalDirector

synopsis: Leading Asian private equity firm Affinity Equity Partners agreed to acquire Sydney-based MedicalDirector (formerly Health Communication Network) from Australia’s Primary Health Care Ltd. MedicalDirector is a leading provider of clinical and enterprise software solutions to general practitioners, medical specialists and allied health professionals.
buyer: Affinity Equity Partners
Affinity Equity Partners is an independently-owned buyout fund manager comprising primarily the former investment professionals of UBS Capital Asia Pacific. They are pioneers in buyout investments in the Asia-Pacific region, with an established and widely recognised franchise. "
target parent: Primary Health Care Limited
target: MedicalDirector
MedicalDirector has been supporting healthcare professionals and improving health outcomes for more than 20 years. They provide software for practice management, optimizing patient outcomes, and access to Australia's most comprehensive and up-to-date pharmaceutical database.
price ($mm)
$119
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/26/2015 via Company Press Release

Inovalon, Inc., will acquire Avalere Health LLC

synopsis: Inovalon, a leading technology company providing cloud-based analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
buyer: Inovalon, Inc. (INOV:$449.36)
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. "
target: Avalere Health LLC
Avalere Health, Inc. is a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
price ($mm)
$140
rev ($mm)
$47
EBITDA ($mm)
EV / rev
3.0x
EV / EBITDA
closed 12/4/2012 via BusinessWire

Decision Resources Group, acquired Abacus International

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it has acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world’s leading healthcare companies.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Abacus International
Abacus International is unique in its provision of services throughout the lifecycle of a pharmaceutical or medical device. They can provide tailored solutions to overcome each hurdle of the product development process, from pre-launch though to market access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
closed 7/20/2017 via PR Newswire

CenterWatch, Inc., acquired FDAnews inc.

synopsis: WIRB-Copernicus Group, the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research, announced that it has acquired FDAnews, which provides global regulatory information for executives in the clinical research, biopharmaceutical and medical device industries.
buyer parent: Arsenal Capital Partners
buyer: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers. "
target: FDAnews inc.
FDAnews provides domestic and international regulatory, legislative and business news and information for executives in industries regulated by the U.S. Food and Drug Administration.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/27/2019 via PR Newswire

The WIRB-Copernicus Group, acquired Waife & Associates, Inc.

synopsis: WIRB-Copernicus Group (WCG) has acquired Waife & Associates, Inc. (W&A), a provider of management consulting services for biopharmaceutical clinical research clients. W&A focuses on making clinical development more efficient and productive through improvements in organization, process, and technology.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WCG (WIRB-Copernicus Group) is the world's leading provider of solutions that improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, clinical research organizations, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: Waife & Associates, Inc.
Waife & Associates (W&A) provides the clinical research industry with management and operational consulting delivered with senior domain expertise. W&A designs cost-effective solutions for clinical operations and data management, and all related functions and software technologies involved.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/30/2019 via Company Press Release

The WIRB-Copernicus Group, acquired First Clinical Research LLC

synopsis: The WIRB-Copernicus Group®’s (WCG™) Market Intelligence & Insights Division has acquired First Clinical Research LLC, organizer of the MAGI (Model Agreements & Guidelines International) Clinical Research Conference. First Clinical also publishes the Journal of Clinical Research Best Practices.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining high safety standards. "
target: First Clinical Research LLC
First Clinical Research LLC is the organizer of the MAGI (Model Agreements & Guidelines International) Clinical Research Conference, which unifies the clinical research ecosystem by facilitating communication and the sharing of best practices among members.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/25/2018 via Company Press Release

The WIRB-Copernicus Group, acquired KMR Group

synopsis: WIRB-Copernicus Group (WCG), the leading provider of solutions to measurably improve the quality and efficiency of clinical research, has acquired KMR Group, a global leader in the provision and analysis of benchmarking and other data for the biopharmaceutical industry.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: KMR Group
KMR Group is a global leader in the provision and analysis of benchmarking and other data for the biopharmaceutical industry. KMR offers leading-edge data, products, and services in the form of reports and on-line tools that inform client strategy and productivity as well as day-to-day operations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/25/2018 via Company Press Release

The WIRB-Copernicus Group, acquired Metrics Champion Consortium

synopsis: WIRB-Copernicus Group (WCG), the leading provider of solutions to measurably improve the quality and efficiency of clinical research, has acquired Metrics Champion Consortium (MCC), an association dedicated to the development of standardized performance metrics to improve clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: Metrics Champion Consortium
Metrics Champion Consortium (MCC) is an association dedicated to the development of standardized performance metrics to improve clinical trials. MCC provides the collaborative environment for biopharmaceutical and device sponsors, service providers, and sites to improve clinical trial development.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/27/2018 via Company Press Release

The WIRB-Copernicus Group, acquired ACI Clinical

synopsis: WIRB-Copernicus Group, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, has acquired ACI Clinical, a specialty provider of clinical trial committees and clinical trial advisory services.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: ACI Clinical
ACI Clinical is a specialty provider of clinical trial committees and clinical trial advisory services. ACI Clinical specializes in clinical and safety consulting, including full service Endpoint Adjudication Committees and Data Monitoring Committees.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/2/2017 via PR Newswire

The WIRB-Copernicus Group, purchased ConsentNow from Patient Genesis

synopsis: WIRB-Copernicus Group announced that it has acquired Patient Genesis' ConsentNow™ eConsent technology. ConsentNow is a web and mobile-based technology platform that allows pharmaceutical, healthcare, or medical device makers to disclose critical information in an easy-to-use, patient-friendly format.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
seller: Patient Genesis
The acquisition includes the ConsentNow™ eConsent technology from Patient Genesis. ConsentNow is a web and mobile-based technology platform that allows pharmaceutical, healthcare, or medical device makers to disclose critical information in an easy-to-use, patient-friendly format.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/9/2017 via PR Newswire

The WIRB-Copernicus Group, acquired MedAvante, Inc.

synopsis: WIRB-Copernicus Group® (WCG™), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, announced that it has acquired MedAvante. MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in global clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: MedAvante, Inc.
MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in clinical trials. With Virgil™, its electronic clinical outcome assessment (eCOA) platform, clinical research sponsors are able to maximize outcome data quality & increase operational efficiency.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/9/2017 via PR Newswire

The WIRB-Copernicus Group, acquired ProPhase, LLC

synopsis: WIRB-Copernicus Group® (WCG™), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, announced that it has acquired ProPhase. ProPhase is a global provider of measurement-related specialty solutions in clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: ProPhase, LLC
ProPhase is a global provider of measurement-related specialty solutions in clinical trials. For over a decade, ProPhase has focused on applying innovation to optimize the selection, use, and analysis of behavioral endpoints to mitigate trial risk and maximize the likelihood of study success.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/2/2017 via PR Newswire

The WIRB-Copernicus Group, acquired ThreeWire, Inc.

synopsis: WIRB-Copernicus Group, the leading provider of solutions that improve the quality & efficiency of clinical research, has acquired ThreeWire, the patient recruitment, enrollment, & retention firm that uses a systematic approach to help biopharmaceutical, medical device companies & clinical research organizations achieve their clinical trial goals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: ThreeWire, Inc.
ThreeWire is the global patient recruitment, enrollment, and retention firm that uses a systematic, patient-focused approach to help biopharmaceutical and medical device companies and clinical research organizations achieve their clinical trial enrollment and retention goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/15/2016 via PR Newswire

The WIRB-Copernicus Group, will purchase Clinical Trial Applications from karmadata

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality of clinical research, will acquire from karmadata a suite of proprietary applications designed to facilitate the management of clinical trial data. karmadata is the market leader in clinical trial database and decision support applications.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
seller: karmadata
Karmadata is able to standardize and link the world's healthcare data ranging from leading open data sources to priva pharmacy and medical claims. Its propriety applications are designed to facilitate the management of clinical trial data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/24/2014 via PR Newswire

The WIRB-Copernicus Group, acquired ePharmaSolutions, Inc.

synopsis: WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced that ePharmaSolutions (ePS) has joined its group of companies. ePharmaSolutions is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of regulatory and ethical solutions for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review. "
target: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of eClinical solutions and specialty clinical services that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2013 via PR Newswire

The WIRB-Copernicus Group, acquired IRBNet

synopsis: Arsenal Capital Partners, a private equity firm that invests in middle market healthcare and specialty industrial companies, announced the acquisition by its portfolio company, The WIRB-Copernicus Group, of Research Dataware, LLC, software developer and provider of IRBNet, the leading software application supporting institutional review boards.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
With more than 60 years of combined experience reviewing research protocols and study-related information, it is the mission of The WIRB-Copernicus Group to meet the highest standards of ethics and science, and to ensure the safety and welfare of subjects worldwide. "
target: IRBNet
IRBNet offers the world's leading and most widely used electronic solution for managing research compliance for institutions of any size, with more than 1,600 large, medium and small research institutions, boards and research sites registered on the National Research Network®.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/16/2015 via PR Newswire

Schulman Associates Institutional Review Board, acquired Absolute Research

synopsis: Schulman Associates IRB, Inc., a customer service and technology company, has acquired Absolute Research. Absolute Research provides protection for human subjects involved in research while supporting a research enterprise. Absolute Research allows research administrators to navigate obstacles for biomedical and social-behavioral research.
buyer: Schulman Associates Institutional Review Board
Schulman Associates IRB is a leader in the protection of human research participants that offers IRB review services to clinical trial sponsors, CROs, and institutions. Schulman offers consulting services that improve clinical studies, data integrity and the protection of human subjects. "
target: Absolute Research
AbsoluteResearch accesses information to advise investigators on regulatory issues and make decisions for an IRB office. Their tools use experiences in IRB Management as well as Bioethics and with their Web-Based Solution they enable Research Institutes to analyze guidance from regulatory agencies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/14/2017 via Company Press Release

Cressey & Co., Spectrum Equity, acquired Verisys Corporation

synopsis: Verisys Corporation, a leading provider of technology solutions and primary-source data on healthcare professionals and businesses, announced that Spectrum Equity, along with Cressey & Company and Verisys CEO John P. Benson, have made a significant growth equity investment in the Company.
buyer: Spectrum Equity
buyer: Cressey & Co.
Spectrum Equity is a leading growth equity firm providing capital and strategic support to innovative Internet, software and information services companies. Cressey & Company LP is a private investment firm focused exclusively on investing in and building leading healthcare businesses. "
target: Verisys Corporation
Verisys is the leading provider of health care credentialing services with the most current, accurate, and comprehensive data and technology tools. Since 1992, Verisys has been leading the health care industry by providing the highest quality data coupled with deep health care industry experience.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/5/2015 via BusinessWire

LexisNexis Risk Solutions, acquired Health Market Science, Inc.

synopsis: LexisNexis® Risk Solutions, a division of Reed Elsevier, announced it has acquired Health Market Science (HMS), a leading supplier of high-quality data on health care professionals and an administrator of one of the largest practitioner-level medical claims databases in the U.S.
buyer parent: Reed Elsevier
buyer: LexisNexis Risk Solutions
LexisNexis Risk Solutions is a leader in providing essential information that helps customers across industries and government predict, assess and manage risk. They are a leading supplier of data and data management solutions for the health care industry. "
target parent: Edison Partners
target: Health Market Science, Inc.
Health Market Science (HMS), helps businesses and government entities solve complex business challenges centered on healthcare provider information. HMS develops agile solutions so their clients can improve compliance, reduce operational costs and maximize market opportunities in real time.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/1/2010 via PR Newswire

Thomson Reuters, acquired Healthcare Data Management, Inc.

synopsis: Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, announced that it has acquired Healthcare Data Management, Inc. Effective immediately, the company will become part of the Healthcare & Science business of Thomson Reuters.
buyer: Thomson Reuters (TRI:$5,921.00)
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. Powered by the world's most trusted news organization, Thomson Reuters combine industry expertise with innovative technology to deliver critical information to leading decision makers. "
target: Healthcare Data Management, Inc.
Healthcare Data Management was a pioneer in the establishment of modeling employee health benefit plans and using data-driven metrics to monitor plan performance.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like CenterWatch, Inc.


read more

CenterWatch, Inc.

HealthiVibe LLC

karmadata

ERT

ERT

CenterWatch, Inc.

CenterWatch, Inc.

Citeline

Advarra

BresMed Health Solutions Ltd

Aureus Sciences

GeneGo Inc.

Decision Resources Group

Dymaxium, Inc.

Context Matters

Vidal Group

MedicalDirector

Avalere Health LLC

Abacus International

Decision Resources Group

read more

FDAnews inc.

CenterWatch, Inc.

CenterWatch, Inc.

CenterWatch, Inc.

read more

Waife & Associates, Inc.

First Clinical Research LLC

KMR Group

Metrics Champion Consortium

ACI Clinical

Patient Genesis

MedAvante, Inc.

ProPhase, LLC

ThreeWire, Inc.

CenterWatch, Inc.

karmadata

ePharmaSolutions, Inc.

IRBNet

read more

Absolute Research

Verisys Corporation

Health Market Science, Inc.

Healthcare Data Management, Inc.

Geography
Matching Companies
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3.com
M3.com
M3.com is Japan's largest portal site dedicated to healthcare professionals. M3.com provides the latest medical news, overseas journal article summaries, and medical resources. The portal offers information on clinical trials and other services in the healthcare and pharmaceutical industries.
year
2019
rev ($mm)
$1,015.17
EBITDA ($mm)
$288.13
EBIT ($mm)
$275.64
Net Income ($mm)
$175.78
Employees
5165
  • drill down
  • watch
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch
Ticker: NYSE:IQV
 
 
 
 
 
 
 
 
IQVIA
IQVIA
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services.
year
2018
rev ($mm)
$10,412.00
EBITDA ($mm)
$1,950.00
EBIT ($mm)
$809.00
Net Income ($mm)
$259.00
Employees
58000
  • drill down
  • watch
Ticker: ENXTPA:CGM
 
 
 
 
 
 
 
 
Cegedim
Cegedim
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases.
year
2018
rev ($mm)
$512.82
EBITDA ($mm)
$50.20
EBIT ($mm)
$33.91
Net Income ($mm)
$6.33
Employees
4468
  • drill down
  • watch